Treating Venous Thromboembolism in Pregnancy

Hematology/Oncology Clinics of North America

Volumn 25, Issue 2, 2011, Pages 379-391

  Fogerty, Annemarie E ^a,b   Connors, Jean M ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diagnostic testing; Heparin; Pregnancy; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; GADOLINIUM; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; PROTEIN S; PROTHROMBIN; THROMBIN INHIBITOR; VON WILLEBRAND FACTOR; WARFARIN;

ABSENCE OF SIDE EFFECTS; ANTICOAGULATION; BACKACHE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CHRONIC VEIN INSUFFICIENCY; COMPRESSION DUPLEX ULTRASONOGRAPHY; COMPRESSION GARMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECHOGRAPHY; EDEMA; FETUS DISEASE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; FRAGILITY FRACTURE; GESTATIONAL AGE; HEART VALVE PROSTHESIS; HUMAN; IN VITRO STUDY; KIDNEY FAILURE; LIMB SWELLING; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MATERNAL MORTALITY; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; OBESITY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; POSTTHROMBOSIS SYNDROME; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RESPIRATION DEPRESSION; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; TACHYCARDIA; TACHYPNEA; THORAX PAIN; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT INDICATION; VEIN THROMBOSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; VENTILATION PERFUSION SCAN; VERTEBRA FRACTURE;

DELIVERY, OBSTETRIC; FEMALE; HEMORRHAGE; HUMANS; LABOR, OBSTETRIC; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 79953046523     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.02.004     Document Type: Review

References (49)

1. Heit J.A., Kobbervig C.E., James A.H., et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005, 143(10):697-706.
2. James A.H., Jamison M.G., Brancazio L.R., et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006, 194(5):1311-1315.
3. Ray J.G., Chan W.S. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999, 54(4):265-271.
4. Simpson E.L., Lawrenson R.A., Nightingale A.L., et al. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001, 108(1):56-60.
5. James A.H., Tapson V.F., Goldhaber S.Z. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol 2005, 193(1):216-219.
6. Weindling A.M. The confidential enquiry into maternal and child health (CEMACH). Arch Dis Child 2003, 88(12):1034-1037.
7. Lockwood C.J. Pregnancy-associated changes in the hemostatic system. Clin Obstet Gynecol 2006, 49(4):836-843.
8. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003, 29(2):125-130.
9. Szecsi P.B., Jorgensen M., Klajnbard A., et al. Haemostatic reference intervals in pregnancy. Thromb Haemost 2010, 103(4):718-727.
10. Kovac M., Mikovic Z., Rakicevic L., et al. The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy. Eur J Obstet Gynecol Reprod Biol 2010, 148(1):27-30.
11. Chan W.S., Ray J.G., Murray S., et al. Suspected pulmonary embolism in pregnancy: clinical presentation, results of lung scanning, and subsequent maternal and pediatric outcomes. Arch Intern Med 2002, 162(10):1170-1175.
12. Scarsbrook A.F., Bradley K.M., Gleeson F.V. Perfusion scintigraphy: diagnostic utility in pregnant women with suspected pulmonary embolic disease. Eur Radiol 2007, 17(10):2554-2560.
13. Scarsbrook A.F., Evans A.L., Owen A.R., et al. Diagnosis of suspected venous thromboembolic disease in pregnancy. Clin Radiol 2006, 61(1):1-12.
14. Anderson D.R., Kahn S.R., Rodger M.A., et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA 2007, 298(23):2743-2753.
15. ACOG Committee on Obstetric Practice ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004, 104(3):647-651.
16. Le Gal G., Righini M. More on: diagnosing pulmonary embolism in pregnancy: rationalizing fetal radiation exposure in radiological procedures. J Thromb Haemost 2005, 3(4):813-814. [author reply: 814-5].
17. Nijkeuter M., Geleijns J., De Roos A., et al. Diagnosing pulmonary embolism in pregnancy: rationalizing fetal radiation exposure in radiological procedures. J Thromb Haemost 2004, 2(10):1857-1858.
18. Ginsberg J.S., Hirsh J., Rainbow A.J., et al. Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 1989, 61(2):189-196.
19. Doshi S.K., Negus I.S., Oduko J.M. Fetal radiation dose from CT pulmonary angiography in late pregnancy: a phantom study. Br J Radiol 2008, 81(968):653-658.
20. Pahade J.K., Litmanovich D., Pedrosa I., et al. Quality initiatives: imaging pregnant patients with suspected pulmonary embolism: what the radiologist needs to know. Radiographics 2009, 29(3):639-654.
21. Hurwitz L.M., Yoshizumi T.T., Reiman R.E., et al. Radiation dose to the female breast from 16-MDCT body protocols. AJR Am J Roentgenol 2006, 186(6):1718-1722.
22. Hopper K.D., King S.H., Lobell M.E., et al. The breast: in-plane x-ray protection during diagnostic thoracic CT-shielding with bismuth radioprotective garments. Radiology 1997, 205(3):853-858.
23. Bates S.M., Greer I.A., Pabinger I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl 6):844S-886S.
24. Duhl A.J., Paidas M.J., Ural S.H., et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007, 197(5). 457, e1--21.
25. Dempfle C.E. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004, 350(18):1914-1915.
26. Mazzolai L., Hohlfeld P., Spertini F., et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006, 108(5):1569-1570.
27. Markwardt F., Fink G., Kaiser B., et al. Pharmacological survey of recombinant hirudin. Pharmazie 1988, 43(3):202-207.
28. Sephton V., Farquharson R.G., Topping J., et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003, 101(6):1307-1311.
29. Laposata M., Green D., Van Cott E.M., et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998, 122(9):799-807.
30. Greer I.A., Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005, 106(2):401-407.
31. Chan W.S., Anand S., Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000, 160(2):191-196.
32. Hall J.G., Pauli R.M., Wilson K.M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980, 68(1):122-140.
33. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993, 168(4):1265-1270.
34. Dahlman T., Lindvall N., Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol 1990, 97(3):221-228.
35. Rodger M.A., Kahn S.R., Cranney A., et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 2007, 5(8):1600-1606.
36. Pettila V., Leinonen P., Markkola A., et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002, 87(2):182-186.
37. Flessa H.C., Kapstrom A.B., Glueck H.I., et al. Placental transport of heparin. Am J Obstet Gynecol 1965, 93(4):570-573.
38. Forestier F., Daffos F., Rainaut M., et al. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemost 1987, 57(2):234.
39. Forestier F., Daffos F., Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound. Thromb Res 1984, 34(6):557-560.
40. Leonhardt G., Gaul C., Nietsch H.H., et al. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis 2006, 21(3):271-276.
41. Turrentine M.A., Braems G., Ramirez M.M. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995, 50(7):534-541.
42. Chunilal S.D., Young E., Johnston M.A., et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002, 87(1):92-97.
43. Dulitzki M., Pauzner R., Langevitz P., et al. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996, 87(3):380-383.
44. Hann C.L., Streiff M.B. The role of vena caval filters in the management of venous thromboembolism. Blood Rev 2005, 19(4):179-202.
45. Billett H.H., Jacobs L.G., Madsen E.M., et al. Efficacy of inferior vena cava filters in anticoagulated patients. J Thromb Haemost 2007, 5(9):1848-1853.
46. Estes J.W., Poulin P.F. Pharmacokinetics of heparin. Distribution and elimination. Thromb Diath Haemorrh 1975, 33(1):26-37.
47. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 1997, 337(10):688-698.
48. Wittmaack F.M., Greer F.R., FitzSimmons J. Neonatal depression after a protamine sulfate injection. A case report. J Reprod Med 1994, 39(8):655-656.
49. Horlocker T.T., Wedel D.J., Rowlingson J.C., et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition). Reg Anesth Pain Med 2010, 35(1):64-101.